前列腺切除术后Decipher基因组检测的前瞻性临床效用与获益研究
该研究纳入两个前瞻性登记队列(2014–2019),评估Decipher肿瘤检测对前列腺切除术后管理的影响。临床效用队列(n=3455)中69%初始推荐观察,检测后39%患者推荐改变,需检测人数为3;临床获益队列(n=135)中基因组高风险者接受推荐ART的2年PSA复发率为3% vs 25%(HR 0.1 [95% CI 0.0-0.6], p=0.013)。
要点
- Decipher检测使39%患者术后治疗决策改变,每3例检测即可改变1例决策。
- 基因组高风险患者接受推荐ART后2年PSA复发率显著低于未接受者(3% vs 25%)。
- 基因组低/中风险患者93%遵循观察推荐,2年PSA复发率与接受ART者相似(p=0.93)。
核心结论
- Decipher基因组检测显著改变前列腺切除术后治疗决策,需检测人数仅为3。
- 对基因组高风险患者常规推荐ART可改善早期生化终点,且不损害低/中风险患者结局。
研究设计与样本
- 研究纳入2014–2019年间治疗的两个前瞻性前列腺癌患者登记队列,均接受Decipher肿瘤检测。
- 临床效用队列(n=3455)评估治疗决策变化,收集不同实践机构泌尿科医生检测前后推荐。
- 临床获益队列(n=135)来自单一学术机构,肿瘤委员会基于GC结果预设「最佳实践」并比较结局差异。
主要发现
- 临床效用队列中,检测前69%推荐观察;检测后39%患者推荐改变,需检测人数为3。
- 临床获益队列中61%患者为基因组高风险;接受推荐ART者2年PSA复发率3%,未接受者为25%(HR 0.1 [95% CI 0.0-0.6], p=0.013)。
- 基因组低/中风险患者中93%遵循观察推荐,其2年PSA复发率与接受ART者相似(p=0.93)。
关键数值与推荐
- 临床效用队列n=3455,检测前观察推荐比例69%,检测后推荐改变比例39%,需检测人数3。
- 临床获益队列n=135,基因组高风险比例61%,ART组2年PSA复发率3% vs 未ART组25%(HR 0.1 [95% CI 0.0-0.6], p=0.013)。
- 基因组低/中风险患者观察推荐遵循率93%,与ART组2年PSA复发率比较p=0.93。
临床怎么用
- 前列腺切除术后具有不良特征的患者可考虑Decipher检测以辅助治疗决策。
- 基因组高风险患者按推荐接受ART可能改善早期生化控制。
- 基因组低/中风险患者可安全采用观察策略,避免过度治疗。
局限性
- 临床获益队列样本量较小(n=135)且来自单一学术机构,结果外推需谨慎。
- 研究为非随机设计,治疗选择可能存在混杂,需更长期随访验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Genomic classifiers (GC) have been shown to improve risk stratification post prostatectomy. However, their clinical benefit has not been prospectively demonstrated. We sought to determine the impact of GC testing on postoperative management in men with prostate cancer post prostatectomy. METHODS: Two prospective registries of prostate cancer patients treated between 2014 and 2019 were included. All men underwent Decipher tumor testing for adverse features post prostatectomy (Decipher Biosciences, San Diego, CA). The clinical utility cohort, which measured the change in treatment decision-making, captured pre- and postgenomic treatment recommendations from urologists across diverse practice settings (n = 3455). The clinical benefit cohort, which examined the difference in outcome, was from a single academic institution whose tumor board predefined "best practices" based on GC results (n = 135). RESULTS: In the clinical utility cohort, providers' recommendations pregenomic testing were primarily observation (69%). GC testing changed recommendations for 39% of patients, translating to a number needed to test of 3 to change one treatment decision. In the clinical benefit cohort, 61% of patients had genomic high-risk tumors; those who received the recommended adjuvant radiation therapy (ART) had 2-year PSA recurrence of 3 vs. 25% for those who did not (HR 0.1 [95% CI 0.0-0.6], p = 0.013). For the genomic low/intermediate-risk patients, 93% followed recommendations for observation, with similar 2-year PSA recurrence rates compared with those who received ART (p = 0.93). CONCLUSIONS: The use of GC substantially altered treatment decision-making, with a number needed to test of only 3. Implementing best practices to routinely recommend ART for genomic-high patients led to larger than expected improvements in early biochemical endpoints, without jeopardizing outcomes for genomic-low/intermediate-risk patients.
引用
- Marascio J, Spratt DE, Zhang J, et al. Prospective study to define the clinical utility and benefit of Decipher testing in men following prostatectomy. Prostate Cancer Prostatic Dis. 2019. PMID: 31719663. doi:10.1038/s41391-019-0185-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。